BPC-157
Evidence: D/ERepair / Tissue Healing
Evidence Snapshot
What this grade covers
Three very small uncontrolled or retrospective human reports exist, but efficacy and general safety remain unestablished; most mechanism and repair evidence is preclinical.
Regulatory Context
No FDA-approved BPC-157 drug product was identified. FDA's 2026 staff evaluation proposed against adding BPC-157 free base and acetate to the 503A Bulks List, citing inadequate characterization, limited effectiveness evidence, and unresolved safety concerns. FDA convened the Pharmacy Compounding Advisory Committee on July 23, 2026; committee recommendations are advisory and do not constitute approval or final agency action. No final FDA action was identified as of the page's review date.
Research Takeaway
BPC-157 is a synthetic 15-amino-acid peptide discussed under inconsistent naming and product-characterization conventions; free base, acetate, and finished products should not be assumed equivalent.
See all 13 evidence claims →Quick Summary
BPC-157 is an experimental 15-amino-acid peptide promoted for repair and gastrointestinal uses. Published human evidence consists of two tiny uncontrolled pilots and one retrospective private-clinic report; most mechanistic support remains preclinical. FDA has identified significant product-characterization, impurity, aggregation, immunogenicity, and long-term safety uncertainties.
Mechanism & Research Overview
Preclinical work reports effects on tendon-cell migration and survival, cytoskeletal organization, FAK/paxillin signaling, nitric-oxide-related pathways, and angiogenic biology. These mechanisms are biologically interesting but do not demonstrate that a marketed BPC-157 product heals human injuries or treats gastrointestinal disease.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
BPC-157 is a synthetic 15-amino-acid peptide discussed under inconsistent naming and product-characterization conventions; free base, acetate, and finished products should not be assumed equivalent.
Sources: FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
A two-person intravenous pilot reported no short-term measured biomarker changes or self-reported adverse effects, but it cannot establish general, long-term, or route-independent safety.
Sources: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Supported
A 12-person uncontrolled interstitial-cystitis pilot reported self-assessed symptom improvement after a single procedure; the study is hypothesis-generating and does not establish efficacy.
Sources: Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Supported
A retrospective knee-pain report found self-reported improvement in many contacted patients, but mixed interventions, lack of controls, nonstandardized outcomes, and variable follow-up prevent causal conclusions.
Sources: Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Supported
Rat tendon-explant and fibroblast experiments reported effects on outgrowth, migration, oxidative-stress survival, and FAK/paxillin signaling; these findings do not establish human tendon healing.
Supported
FDA identifies immunogenicity, aggregation, peptide-impurity, product-characterization, formulation, concentration, and storage concerns for compounded BPC-157.
Sources: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — BPC-157; FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
FDA’s 2026 evaluation found insufficient evidence of effectiveness for ulcerative colitis and proposed against adding BPC-157 free base and acetate to the 503A Bulks List.
Sources: FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
FDA convened the Pharmacy Compounding Advisory Committee on July 23, 2026 to discuss BPC-157-related bulk drug substances. The meeting and any advisory recommendation did not create FDA approval or final agency action.
Sources: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page; FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
The reviewed human evidence consists of a two-person intravenous pilot, a 12-person uncontrolled interstitial-cystitis report, and a retrospective knee-pain report; these studies do not establish efficacy for tendon, ligament, cartilage, muscle, gastrointestinal, or other commonly marketed indications.
Sources: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study; Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Supported
Reuters reported that on July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend possible inclusion of BPC-157 on the 503A Bulks List. The available secondary report did not distinguish between the free-base and acetate voting questions. The recommendation was advisory and nonbinding. It did not itself place BPC-157 on the 503A Bulks List, create FDA approval, establish safety or effectiveness, authorize a consumer product, or create an approved dosing regimen. No subsequent final FDA action was identified in the sources reviewed as of July 26, 2026.
Sources: Advisory Panel Vote on BPC-157
Supported
BPC-157 appears on the World Anti-Doping Agency's prohibited list under the non-approved-substances category; this sports rule is separate from FDA drug approval and compounding law.
Sources: The 2026 Prohibited List
Supported
Independent 2026 reviews of BPC-157's musculoskeletal evidence base and its translational-development barriers confirm that the broad preclinical literature has not translated into large randomized controlled human trials, and that much of the historical literature originates from a limited investigator network with unresolved formulation and replication barriers.
Sources: BPC-157 Musculoskeletal Evidence Review; BPC-157 Translational Development Barriers
Supported
A registered 2026 trial (NCT07437547) is investigating BPC-157 for acute grade-II hamstring injury. Registration or recruitment status does not establish safety or effectiveness and should not be reported as a positive result.
Sources: BPC-157 for Acute Hamstring Strain
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The published reports cannot establish efficacy, rare harms, long-term safety, or broad route equivalence.Safety Consideration
FDA found inconsistent naming and inadequate data for identity, aggregates, impurities, microbial quality, endotoxins, and other critical quality attributes.Safety Consideration
Peptide synthesis, formulation, concentration, storage, and route can change aggregation, impurities, pharmacological activity, and immune risk.Safety Consideration
Tendon-cell and animal-model effects should not be presented as proof of tendon, ligament, cartilage, muscle, or gastrointestinal repair in people.Safety Consideration
FDA staff proposed against 503A listing, but the July 23, 2026 advisory meeting had not occurred on the research review date.Safety Consideration
The 8-6 advisory-committee vote favoring possible 503A-list inclusion did not create FDA approval, establish safety or effectiveness, or create an approved dosing regimen. Final FDA action was not identified as of 2026-07-26.
Research Areas Being Studied
Research areas discussed on this page reflect the Repair / Tissue Healing category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025):
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024):
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study | 2025 | Two adults with prior intravenous BPC-157 exposure | No adverse effects or measured biomarker changes were reported after two consecutive-day infusions. | Two previously exposed participants, no control group, short follow-up, and limited outcome assessment prevent general safety conclusions. | Lee E, Burgess K. Altern Ther Health Med. 2025;31(5):20-24. PMID:40131143. |
| Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study | 2024 | Twelve women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate | Participants reported substantial symptom improvement on a Global Response Assessment after one procedure. | No control group, blinding, standardized comparator, independent replication, or robust adverse-event ascertainment. | Lee E, et al. Altern Ther Health Med. 2024;30(10):12-17. PMID:39325560. |
| Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain | 2021 | Sixteen contacted patients from a 17-patient retrospective chart review | Most contacted patients reported pain improvement, but outcomes were nonstandardized and the intervention was mixed in four patients. | No control group, inconsistent follow-up, heterogeneous diagnoses, self-reported pain, no standardized function or imaging outcomes, and a mixed-combination subgroup. | Lee E, Padgett B. Altern Ther Health Med. 2021;27(4):8-13. PMID:34324435. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration | 2011 | Rat tendon explants and cultured rat tendon fibroblasts | BPC-157 increased explant outgrowth, cell survival under oxidative stress, migration, spreading, and FAK/paxillin phosphorylation in the experimental systems. | Cell and tissue findings do not establish human tendon healing, injury recovery, or clinical safety. | Chang CH, et al. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Advisory Panel Vote on BPC-157 | 2026 | On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend possible 503A-list inclusion for BPC-157. The vote was advisory and nonbinding and did not create FDA approval, establish safety or effectiveness, or authorize a consumer product. | |||
| Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — BPC-157 | 2026 | FDA compounding safety review | FDA identifies route-dependent immunogenicity, peptide-impurity, API-characterization, and insufficient safety-information concerns. | FDA states that it lacks sufficient information to know whether compounded BPC-157 would cause harm when administered to humans by the proposed routes. | FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Reviewed 2026-07-19. |
| FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List | 2026 | FDA Pharmacy Compounding Advisory Committee briefing | FDA found BPC-157 insufficiently characterized, found insufficient evidence of effectiveness for ulcerative colitis, and proposed that free base and acetate not be added to the 503A Bulks List. | FDA highlighted aggregation, peptide impurities, route- and formulation-specific risk, inadequate long-term clinical safety, and uncertain adverse-event causality. The proposal preceded the July 23, 2026 committee meeting and was not a final committee outcome on the review date. | FDA Briefing Document: BPC-157-related bulk drug substances. May 11, 2026. |
| July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page | 2026 | FDA advisory-committee calendar | The meeting was scheduled after the MitoCore research review date, so no final committee vote or post-meeting FDA action was available for this pack. | Regulatory wording must be updated after the meeting and any subsequent FDA action. | FDA advisory committee calendar. July 23-24, 2026 PCAC meeting. |
| The 2026 Prohibited List | 2026 | Anti-doping regulatory list | BPC-157 is prohibited at all times under the 2026 WADA list. | Anti-doping status is not a clinical safety or efficacy determination. | |
| BPC-157 for Acute Hamstring Strain | A registered 2026 trial is designed to investigate BPC-157 for acute grade-II hamstring injury. Registration or recruitment status does not establish safety or effectiveness and should not be reported as a positive result. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| BPC-157 Musculoskeletal Evidence Review | A 2026 review of BPC-157 musculoskeletal evidence found that human clinical evidence remains limited to small, uncontrolled, or retrospective reports and does not establish that BPC-157 heals tendons, ligaments, muscle, or cartilage in humans. | ||||
| BPC-157 Translational Development Barriers | A 2026 review of BPC-157 translational development barriers found that much of the historical preclinical literature originates from a limited investigator network, and that formulation, replication, and translation to human trials remain significant unresolved barriers. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
BPC-157 remains experimental. Small uncontrolled human reports and preclinical studies do not establish a safe or effective treatment for injury repair, pain, gastrointestinal disease, or recovery.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Website/CMS content draft; source verification and legal/privacy review required before public launch. Last updated 2026-07-26.
Follow research updates for BPC-157
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.